# A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06868485/  
OnCo record `nct06868485` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of WSD0922-FU Tablets, Dose level A in non-small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.

## Summary

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT06868485 by Wayshine Biopharm, Inc., with 40 participants planned, started 2025-08-18 and due to reach its primary completion in 2027-09-30. Interventions recorded: WSD0922-FU Tablets, Dose level A and WSD0922-FU Tablets, Dose level B.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06868485
- Phase: 2
- Setting: A Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With First-Line Osimertinib Treatment and Harbor a C797S Mutation
- Sponsor: Wayshine Biopharm, Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06868485: https://clinicaltrials.gov/study/NCT06868485

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06868485.json